alleviates experimentally acetic acid- induced ulcerative colitis in rats: targeting CB1/SIRT/MAPK signaling pathways.

BACKGROUND

Ulcerative colitis (UC) is a frequent inflammatory bowel disease (IBD) that causes long-lasting inflammation in the innermost lining of the rectum and colon.

OBJECTIVE

The aim of this study was to evaluate the therapeutic effect of () on the amelioration of acetic acid-induced colitis in rats.

MATERIALS AND METHODS

Group 1: normal control group was intrarectally administered saline solution (0.9%); group 2: acetic acid (AA) group was given AA intra-rectally (2 mL of 4% (v/v) in 0.9% NaCl) once.; group 3&4: This group represented the ulcerative colitis-induced rats that were injected with acetic acid intra-rectally, then s.c. injection with (20 and 40 mg/kg daily for 8 days).

RESULTS

Colonic architectural abnormality significantly improved after pretreatment with . Additionally, it significantly reduced the MDA level and prevented the depletion of GSH content. Moreover, administration showed suppressive activities on pro-inflammatory cytokines, including NF-κB, MAPK, ERK, PI3K, AKT, HIF-1α, and TLR4. Moreover, it significantly upregulated the level of SIRT and CB1 in the colon tissue.

CONCLUSION

This study provided a novel impact for CB1 receptor activation produced by against AA-induced UC in rats through inhibiting the TLR-4 MAPK/ERK, PI3K, and NFκB signaling pathways.